Steven Valiquette
Stock Analyst at Mizuho
(3.22)
# 1,111
Out of 5,118 analysts
121
Total ratings
50.77%
Success rate
2.12%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Maintains: Outperform | $36 → $28 | $17.00 | +64.71% | 2 | Dec 10, 2025 | |
| LFMD LifeMD | Maintains: Neutral | $8 → $6 | $3.44 | +74.42% | 2 | Nov 19, 2025 | |
| GDRX GoodRx Holdings | Maintains: Neutral | $5 → $4 | $2.69 | +48.70% | 1 | Nov 6, 2025 | |
| COR Cencora | Maintains: Outperform | $340 → $380 | $340.25 | +11.68% | 3 | Nov 6, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $170 → $210 | $207.38 | +1.26% | 7 | Nov 4, 2025 | |
| WAY Waystar Holding | Maintains: Outperform | $48 → $50 | $32.94 | +51.79% | 2 | Oct 30, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $210 → $170 | $157.84 | +7.70% | 12 | Oct 13, 2025 | |
| MCK McKesson | Maintains: Neutral | $750 → $770 | $830.42 | -7.28% | 4 | Sep 24, 2025 | |
| VEEV Veeva Systems | Maintains: Outperform | $295 → $325 | $225.02 | +44.43% | 4 | Aug 29, 2025 | |
| NVST Envista Holdings | Maintains: Underperform | $15 → $18 | $21.81 | -17.47% | 2 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $6.93 | +44.30% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $60 | $44.23 | +35.65% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $18 | $11.25 | +60.00% | 7 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $82 | $80.09 | +2.38% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $92.78 | +35.81% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $75 | $76.44 | -1.88% | 5 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.58 | +39.66% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $14 | $2.76 | +407.25% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $226.11 | -37.20% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $79.65 | -30.95% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $189.64 | -51.49% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $328.94 | +71.76% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $80.02 | +24.97% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $5.09 | +175.05% | 1 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $166.54 | +140.18% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $40.81 | +162.19% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $37.07 | -54.14% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $10.83 | +10.80% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $107.96 | -11.08% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $175.52 | -31.63% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $474.02 | -73.21% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $258.34 | +38.58% | 3 | Dec 6, 2019 |
Phreesia
Dec 10, 2025
Maintains: Outperform
Price Target: $36 → $28
Current: $17.00
Upside: +64.71%
LifeMD
Nov 19, 2025
Maintains: Neutral
Price Target: $8 → $6
Current: $3.44
Upside: +74.42%
GoodRx Holdings
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $2.69
Upside: +48.70%
Cencora
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $340.25
Upside: +11.68%
Cardinal Health
Nov 4, 2025
Maintains: Outperform
Price Target: $170 → $210
Current: $207.38
Upside: +1.26%
Waystar Holding
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $32.94
Upside: +51.79%
Align Technology
Oct 13, 2025
Maintains: Outperform
Price Target: $210 → $170
Current: $157.84
Upside: +7.70%
McKesson
Sep 24, 2025
Maintains: Neutral
Price Target: $750 → $770
Current: $830.42
Upside: -7.28%
Veeva Systems
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $225.02
Upside: +44.43%
Envista Holdings
Aug 1, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $21.81
Upside: -17.47%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $6.93
Upside: +44.30%
May 16, 2025
Maintains: Neutral
Price Target: $65 → $60
Current: $44.23
Upside: +35.65%
Mar 13, 2025
Maintains: Neutral
Price Target: $21 → $18
Current: $11.25
Upside: +60.00%
Mar 3, 2025
Maintains: Neutral
Price Target: $70 → $82
Current: $80.09
Upside: +2.38%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $92.78
Upside: +35.81%
Dec 4, 2024
Initiates: Neutral
Price Target: $75
Current: $76.44
Upside: -1.88%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $3.58
Upside: +39.66%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $18 → $14
Current: $2.76
Upside: +407.25%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $226.11
Upside: -37.20%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $79.65
Upside: -30.95%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $189.64
Upside: -51.49%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $328.94
Upside: +71.76%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $80.02
Upside: +24.97%
Feb 27, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $5.09
Upside: +175.05%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $166.54
Upside: +140.18%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $40.81
Upside: +162.19%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $37.07
Upside: -54.14%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $10.83
Upside: +10.80%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $107.96
Upside: -11.08%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $175.52
Upside: -31.63%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $474.02
Upside: -73.21%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $258.34
Upside: +38.58%